Last Price
11.80
Today's Change
+1.94 (19.67%)
Day's Change
9.50 - 12.15
Trading Volume
568,417
Market Cap
8 Million
Shares Outstanding
696,249
Avg Volume
1,664,115
Avg Price (50 Days)
6.35
Avg Price (200 Days)
17.99
PE Ratio
0.00
EPS
5571.72
Earnings Announcement
28-Mar-2025
Previous Close
9.86
Open
9.81
Day's Range
9.5 - 12.15
Year Range
2.66 - 66.33
Trading Volume
583,534
1 Day Change
19.68%
5 Day Change
4.15%
1 Month Change
259.76%
3 Month Change
-10.54%
6 Month Change
36.89%
Ytd Change
234.28%
1 Year Change
-49.49%
3 Year Change
-99.98%
5 Year Change
-99.99%
10 Year Change
-99.99%
Max Change
-99.99%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.